Author of the publication

Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study

, , , , , , , , , , , , , , , , , and . The Lancet Oncology, 9 (5): 435–444 (2008)

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

 

Other publications of authors with the same name

Robust and automated unimodal histogram thresholding and potential applications., , , , and . Pattern Recognit., 37 (6): 1131-1148 (2004)CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group, , , , , , , , , and 11 other author(s). The Lancet Oncology, 12 (11): 1013–1022 (2011)Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study, , , , , , , , , and 8 other author(s). The Lancet Oncology, 9 (5): 435–444 (2008)CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group, , , , , , , , , and 14 other author(s). The Lancet. Oncology, 7 (5): 379–391 (2006)Thresholding based on linear diffusion for feature segmentation., , , , and . BMVC, page 1-10. BMVA Press, (2003)